TABLE 2.
Type, prevalence, and outcomes of AEs
| Characteristic | Total (N = 40) | |
|---|---|---|
| Patients with AEs, n (%) | 4 (10.00) | |
| Patients with AEs > 1, n (%) | 2 (5.00) | |
| Type of AEs, n (%) | Hypertension | 2 (5.00) |
| Hyperglycemia | 1 (2.50) | |
| Albumin decline | 1 (2.50) | |
| Abnormal liver function | 1 (2.50) | |
| Stomach discomfort | 1 (2.50) | |
| NR dosage of patients with AEs, n (%) | 300 + 100 mg bid | 2 (5.00) |
| 150 + 100 mg bid | 1 (2.50) | |
| 300 + 100 mg qd | 1 (2.50) | |
| AEs with a maximum grade of ≥3a | 0 (0.00) | |
| Admission, yes, n (%) | 0 (0.00) | |
| Admission to ICU, n (%) | 0 (0.00) | |
| Death, yes, n (%) | 0 (0.00) | |
a
Severity grades were defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. For events not listed in the NCI CTCAE, version 5.0, severity was determined according to prespecified criteria listed in the protocol.